Summary: The constitutive expression of CYP2D9 is sexually dimorphic, namely, strong in males, but diminutive in females. Repetition of mimic growth hormone (GH) secretion pattern impressively returned the mRNA expression level to that in intact mice: the GH secretion pattern's regulation of CYP2D9 mRNA expression has been predominantly disrupted by exogenous GH-administration. The extensive decline of CYP2D9 mRNA expression becoming a sexually non-speciˆc P450 in 9-week-old male mice exposed as neonates to monosodium L-glutamate (MSG) suggested that the male GH secretion pattern is a key to the regulation of male-speciˆc CYP2D9 mRNA expression in adult mice. Dexamethasone (Dex) showed possibility to induce CYP2D9 mRNA expression in adult MSG-neonatally treated mice of either sex. However, the antagonism was observed by co-administration of Dex and GH in the males. Dex-administration in adrenalectomized mice signiˆcantly elevated CYP2D9 mRNA expression levels. Theseˆndings suggest that an adrenal hormone participates in the regulatory mechanism of CYP2D9 mRNA expression in association with GH.
Introduction
The hepatic metabolism of steroids and xenobiotics catalyzed by cytochrome P450s (P450s) is sexually dimorphic in rodents, humans, and other animals. 1, 2) Certain metabolism by sex-speciˆc P450s may lead to sex-dependent susceptibility to chemical toxicity and carcinogenicity.
3) CYP3A4, a major drug-metabolizing P450 responsible for the metabolism of over 50z of therapeutic drugs, exhibits stronger activity in women than in men. 4, 5) In contrast, the level of activity of other P450 (CYP2C19, CYP2D6, and CYP2E1) isoenzymes and conjugation (glucuronidation) involved in drug metabolism may be higher in men than in women. 2) However, some observations demonstrate theˆnding of a lack of sex diŠerences of CYP2C19, CYP2D6, and CYP2E1 activities in drug metabolism. [6] [7] [8] Therefore, presently, it is not conˆrmed whether sex is relevant in hepatic metabolism of drugs and xenobiotics by cytochrome P450 in human. Although several molecular and W or cellular mechanisms of transcriptional regulation of sex-speciˆc P450s have been proposed in animals, [9] [10] [11] deˆning the regulatory mechanism remains to be a consequential interest in continuous investigations.
The sexually dimorphic, ultradian rhythms in the circulating growth hormone (GH) proˆle have been shown to regulate the sex-dependent expression of hepatic monooxygenases in rats and mice. 12, 13) Moreover, a recent report showed that the secretion of GH in humans is also sexually dimorphic, with pulsatile GH decreasing, but continuous GH infusion increasing, CYP3A4 activity. 14) The mouse Cyp2d9 gene encodes the male-speciˆc steroid 16a-hydroxylase which might participate in the synthesis of estrogens. 9, 15, 16) GH activates Cyp2d9 gene expression in GH-deˆcient Little mice, dictating the male phenotype of the P450 genes. 9) However, the female phenotype (i.e., repression of CYP2D9) is not regulated by GH, 16) although its diminutive expression is constitutive. Regarding GH, pulsatile GH secretion (i.e., the male pattern) elicits Stat5b nuclear translocation, suggesting Stat5b to be a direct transcription factor regulating the sex-speciˆc CYP2C11 and CYP2C12 genes in rats. 17, 18) Experiments with Stat5b-deˆcient mice have shown that Stat5b regulates the expression of the Cyp2a4 and Cyp2d9 genes in males, but the deˆciency does not aŠect the genes in females. 11) Besides GH, endogenous glucocorticoid or adrenal hormones and synthetic glucocorticoid hormones such as dexamethasone (Dex), have been shown to modulate the expression of mouse-hepatic P450s in diŠerent ways. [19] [20] [21] For instance, Dex markedly induced CYP2B10 expression dose-dependently, but simultaneously suppressed CYP2B9 expression both in vivo and in a hepatocyte culture. 19) Adrenalectomy, attending the eŠect of the endogenous glucocorticoid hormone, increased the expression of both CYP2B9 and CYP2B10 mRNAs, especially that of CYP2B9 in the male liver. 19) On the other hand, some isoenzymes of the Cyp3a gene are inducible by Dex. [21] [22] [23] Theseˆndings indicate that P450s may have a much more speciˆc and complex physiologic expression mechanism than is currently recognized. 24, 25) Neonatal administration of monosodium L-glutamate (MSG) to rats, mice, and possibly other species produces a profound, but rather selective growth hormone deˆciency, resulting in a well-deˆned syndrome characterized by stunted growth and obesity. [26] [27] [28] [29] AŠected adults exhibit abnormalities in both the secretion of GH and the expression of P450s. 17, 30) Neonatal administration of MSG induces hypothalamic lesions, subsequently blocks GH secretion, permanently and rather selectively. These results in a severe reduction in hepatic monooxygenase activities and re‰ects in part the repression of some sex-dependent P450s in the rodents. [31] [32] [33] Since neonatal exposure to MSG has been proven to induce GH depletion in rats, a useful model for studying the regulation by GH of hepatic monooxygenases, 30, [32] [33] [34] it is worth examining the contribution of glucocorticoid and growth hormones to the expression of mouse-hepatic CYP2D9 mRNA.
The present study deals with the regulation of malespeciˆc CYP2D9 mRNA expression by glucocorticoid and growth hormones in mouse liver. A pulsatile pattern of GH secretion is a key to the regulatory mechanism of CYP2D9 mRNA expression in adult mice. Furthermore, the regulation could be disrupted by exogenously administered GH. Besides GH, new evidence that endogenous glucocorticoid or adrenal hormones exert a role in the regulatory pathway of CYP2D9 mRNA expression has been obtained.
Materials and Methods
Materials: An Alzet } micro-osmotic pump, model 1007D, was obtained from Durect Corporation (Cupertino, CA). Human recombinant growth hormone (rhGH) and monosodium L-glutamate (MSG) were supplied by Wako Pure Chemical (Osaka, Japan). Dexamethasone (Dex) was purchased from Sigma Chemical Co. (St. Louis, MO). TaqMan } reverse transcription reagents, TaqMan } PCR core reagent kit, TaqMan } Gene Expression Assay, and SYBR } Green PCR Mater Mix were products of Applied Biosystems (Branchburg, NJ). All other laboratory chemicals were of the highest purity and from commercial suppliers.
Animals: Animals were housed in the University of Toyama's Animal Center facility, under the supervision of certiˆed laboratory veterinarians and were treated according to a research protocol approved by the University's Institutional Animal Care and Use Committee. At all times, animals were housed on paper chip bedding in plastic cages, with water and commercial mouse diet supplied ad libitum. The animal quarters were air conditioned (20-239 C) and had a 12-h light W dark cycle. Seven-week-old female and male C57BL W 6NCrj mice (Charles River, Kanazawa, Japan) were subcutaneously injected with rhGH (50 mg W mouse) or a 0.9z normal saline solution (NSS) every 12 h or received an osmotic infusion (1.5 mg W h) of rhGH or NSS for 7 days. 9, 21, 23, 35) The infusion with a micro-osmotic pump, the Alzet } 1007D, implanted on the back of the mouse, was designed to deliver the solution at a rate of 0.5 mL W h. Pregnant C57BL W 6NCrj mice were supplied by Charles River (Kanazawa, Japan). In reference to the established protocol for MSG-neonatally administration for mice with circulating plasma GH monitor, 31) within 24 h after birth and on alternate days for theˆrst 9 days of life, the pups were subcutaneously injected with MSG at 2 mg W g body weight for a total ofˆve times. The pups were weaned at ¿28 days of age. Replacement of MSG-neonatally treated mice with rhGH or Dex began at 8 weeks of age. rhGH was dissolved in a 10 mM Tris･HCl (pH 8.0)-NSS and administered by either subcutaneous injection at a dose of 50 mg W injection twice daily or continuous infusion using a subcutaneously implanted micro-osmotic pump at a rate of 1.5 mg W h for 7 days. Dex in corn oil was given by daily subcutaneous injection at a dose of 0.1 mg W g W day for 3 days. 19, 21, 35) The vehicle control group received NSS or corn oil (for Dex), though the vehicle did not signiˆcantly change CYP2D9 mRNA Fig. 1 . Expression of CYP2D9 mRNA in the liver of GH-treated intact C57BL W 6 mice. Seven-week-old male and female C57BL W 6 mice received an osmotic infusion or subcutaneous injection of recombinant human GH every 12 h for 7 days, respectively. The mRNA level of CYP2D9 was normalized to that of GAPDH and is shown relative to the level in un-treated male mice. Each column represents the mean±SD (n＝4). NSS (sc), twice daily subcutaneous injection of NSS; GH (sc), twice daily subcutaneous injection of rhGH; NSS (i), continuous infusion of NSS using a micro-osmotic pump; GH (i), continuous infusion of rhGH using a micro-osmotic pump. Signiˆcance was examined using the nonparametric Mann-Whitney U test; *pº0.01 and **pº0.001 (vs. NSS (sc) group of each sex); # pº0.05 and ## pº0.001 (vs. NSS (i) group of each sex).
expression (unpublished observation). Veriˆcation of MSG-treatment was conˆrmed by growth retardation. GH replacement was checked by examining body weight gain. Adrenalectomized C57BL W 6NCrj mice of both sexes (Charles River) were daily subcutaneously administered Dex at a dose of 0.01 mg W g W day for 4 days. The mice were sacriˆced a day after the last day of treatment and the liver was excised immediately for preparation of total RNA. Real-time RT-PCR: Mouse CYP2D9 and GAPDH mRNAs were quantiˆed by real-time RT-PCR. Hepatic total RNA was isolated as described elsewhere, 19, 36) and cDNAs were synthesized under the conditions recommended by the supplier (Applied Biosystems, Branchburg, NJ) of the TaqMan } Gold RT-PCR kit using a speciˆc TaqMan } Gene Expression Assay for Cyp2d9 (ID no. Mm00651731  m1) and the SYBR } Green PCR Mater Mix for GAPDH, in which the forward and reverse primers for GAPDH were 5?-TCC ACT CAC GGC AAA TTC AAC G-3? and 5?-TAG ACT CCA CGA CAT ACT CAG C-3?, respectively. PCR was performed using the ABI Prism } 7000 Sequence Detection System (Applied Biosystems) with ABI Prism } 7000 SDS software. The PCR conditions were as follows: the activation of AmpErase UNG and AmpliTaq Gold at 509 C for 2 min and 959 C for 10 min, respectively, then the ampliˆcation with denaturation at 959 C for 15 s, and annealing and extension at 609 C for 1 min (CYP2D9, 55 cycles; GAPDH, 44 cycles). The ampliˆed products of CYP2D9 were detected directly by monitoring the ‰uorescence of the reporter dye (FAM), by which an increase in ‰uorescence signal was detected only if the target sequence was complementary to the probe and ampliˆed during the PCR. On the other hand, those of GAPDH were monitored directly by measuring the increase in SYBR } Green that bound to double-stranded DNA ampliˆed by PCR.
Results
Expression of CYP2D9 mRNA in the liver of GHtreated intact C57BL W 6 mice: The level of CYP2D9 mRNA expression was constitutively high in the males, while that in females was diminutive (Fig. 1) as in our previous report. 35) To investigate the function of GH secretion pattern in the regulation of the sex-speciˆc Cyp2d9 gene in vivo, secretion of GH was mimicked in intact mice of both sexes by osmotic infusion (female type) or twice daily subcutaneous injection (male type) of rhGH or NSS for 7 days. Impressively, mimicking repetition of GH consistently achieved an expression similar to that in the intact mice. Twice daily injections of rhGH signiˆcantly promoted CYP2D9 mRNA expression in female mice, whereas continuous infusion of rhGH markedly diminished the expression in males. The results revealed that the GH secretion pattern's regulation of CYP2D9 mRNA expression was disrupted by exogenously administered GH.
Expression proˆle of CYP2D9 mRNA in the liver of Fig. 2 . Expression proˆle of CYP2D9 mRNA in the liver of C57BL W 6 mice neonatally administered with MSG. MSG-neonatally treated male and female mice were killed at 3 and 9 weeks of age. At 8 weeks of age, some MSG-neonatally treated male and female mice were subcutaneously injected with rhGH (50 mg W mouse) every 12 h and received an osmotic infusion (1.5 mg W h) of rhGH for 7 days, respectively, and were killed on the day after the last day of treatment. The mRNA level of CYP2D9 was normalized to that of GAPDH and is shown relative to the level in un-treated male mice. Each column represents the mean±SD (n＝4). 3, 3 weeks of age; 9, 9 weeks of age; NT, no treatment; MSG, neonatal administration of MSG; GH (i), continuous infusion of rhGH using a micro-osmotic pump; GH (sc), twice daily subcutaneous injection of rhGH. Signiˆcance was examined using the nonparametric Mann-Whitney U test; *pº0.05, **pº0.01, and ***pº0. C57BL W 6 mice neonatally administered MSG: At a dose of 2 mg W g body weight, MSG had detrimental eŠects on the growth of C57BL W 6 mice of both sexes. At 3 weeks of age, the CYP2D9 mRNA was expressed at similarly low levels regardless of sex, in both the control and MSG-neonatally treated mice (Fig. 2) . In contrast, a sex-diŠerence in CYP2D9 mRNA expression was clearly noticeable at 9 weeks of age in intact mice: the level of expression was high in the males, whereas it was drastically low in the females. Unlike the intact male mice, both sexes of 9-week-old MSG-neonatally treated mice showed diminutive expression of CYP2D9 mRNA. CYP2D9, thus, becomes sexually nonspeciˆc in MSGneonatally treated mice. Replacement of GH in 9-weekold mice neonatal exposure to MSG, by twice daily administration of rhGH, mimicking the male GH secretory proˆle, fully restored the CYP2D9 mRNA expression in the males, nevertheless continuous infusion of rhGH mimicking the female GH secretory proˆle sustained the low level of CYP2D9 mRNA expression in the females. EŠect of GH and Dex on the expression of CYP2D9 mRNA in the liver of C57BL W 6 mice neonatally administered MSG: Dex markedly induced CYP2D9 mRNA expression in 9-week-old MSG-neonatally treated mice of both sexes, albeit at a much higher intensity in the females (Fig. 3) . GH exerted diŠerent eŠects on the CYP2D9 mRNA expression, depending on the prototypes of GH circulation: the expression was promoted by twice daily administration of rhGH (male type), but signiˆcantly suppressed by osmotic infusion of rhGH (female type). The GH-inducible expression of CYP2D9 mRNA in the males was antagonized by coadministration of GH and Dex, resulting the induction of expression was similar to that by Dex itself. On the other hand, Dex partially restored the repressive eŠect of female type rhGH administration in the females. These observations suggest for theˆrst time that either Dex is a remarkable CYP2D9 mRNA inducer or the female type administered GH is a repressive factor of CYP2D9 mRNA expression in the mouse liver.
Expression of CYP2D9 mRNA in the liver of C57BL W 6 mice after adrenalectomy: Besides STAT5b, 11) estrogen receptor-a, 9) as well as GH (35, hereinbefore), endogenous glucocorticoid or adrenal hormone plays a role in the regulatory pathway of CYP2D9 mRNA expression. Therefore, we further investigated how the expression of hepatic CYP2D9 mRNA was modulated after adrenalectomy. To observe the eŠect of endogenous glucocorticoid or adrenal hormones on the expression of CYP2D9 mRNA, adrenalectomy was performed in C57BL W 6 mice. The level of CYP2D9 mRNA expression was signiˆcantly decreased by half in the adrenalectomized mice of both sexes (Fig. 4) . Dex Fig. 3 . EŠect of GH replacement and Dex on the expression of CYP2D9 mRNA in the liver of C57BL W 6 mice neonatally administered with MSG. At 8 weeks of age, MSG-neonatally treated male and female mice were subcutaneously injected with Dex at a dose of 0.1 mg W g W day for 3 days as well as rhGH (50 mg W mouse) every 12 h or received an osmotic infusion (1.5 mg W h) of rhGH for 7 days, respectively, and were killed on the day after the last day of treatment. The mRNA level of CYP2D9 was normalized to that of GAPDH and is shown relative to the level in un-treated male mice. Each column represents the mean±SD (n＝4). NT, no treatment; Dex, dexamethasone; GH (i), continuous infusion of rhGH using a micro-osmotic pump; GH (sc), twice daily subcutaneous injection of rhGH; MSG, neonatal administration of MSG. Signiˆcance was examined using the nonparametric Mann-Whitney U test; *pº0.05, **pº0.01 (vs. un-treated mice of each sex). Fig. 4 . Expression of CYP2D9 mRNA in the liver of C57BL W 6 mice after adrenalectomy. Adrenalectomized or sham-operated C57BL W 6 mice were subcutaneously injected with Dex at a dose of 0.01 mg W g W day. All mice were killed 5 days after the operation. The mRNA level of CYP2D9 was normalized to that of GAPDH and is shown relative to the level in un-treated male mice. Each column represents the mean±SD (n＝4-6). NT, no-treatment; Dex, dexamethasone; Sham, sham-operation; Adx, adrenalectomy. Signiˆcance was examined using the nonparametric MannWhitney U test; *pº0.05, **pº0.01, and ***pº0.001 (vs. sham-operated-un-treated mice of each sex); # pº0.001 (vs. adrenalectomized mice of the same sex).
signiˆcantly raised the level of CYP2D9 mRNA in the females, but not in the males. Administration of Dex in adrenalectomized mice signiˆcantly elevated CYP2D9 mRNA levels. Theseˆndings lately suggested that glucocorticoid or adrenal hormones partly participated in the expression mechanism of CYP2D9 mRNA.
Discussion
The constitutive expression of CYP2D9 mRNA consistently demonstrates that pulsatile GH is an essential factor for masculinization CYP2D9 mRNA expression in male mice. 9, 16, 35) The disruption of GH secretion pattern's regulation of CYP2D9 mRNA expression by exogenously administered GH revealed that the proˆle of GH administration was a predominant regulatory factor for the expression of sex-speciˆc P450s, corresponding to a previous reports. 35) The decline in the level of CYP2D9 mRNA caused by neonatal exposure to MSG could be explained by the permanent absence or very low level of GH in the circulation for its entire life, including the critical period of diŠerentiation of the hypothalamic-pituitary-hepatic axis. 1) In addition, repetition of pulsatile GH secretory proˆle to 9-week-old-MSG-neonatally treated mice fully restored the CYP2D9 mRNA expression in the males, in accordance with a previous report using GH-deˆcient Little mice. 16) These results suggested that the male secretion pattern of GH secretion is an authoritative key to the regulatory mechanism of male-speciˆc CYP2D9 mRNA expression in the adult mice.
The diŠerent expression of CYP2D9 mRNA in intact and MSG-neonatally treated mice of both sexes by Dex was observed. Dex induced expression of CYP2D9 mRNA in both intact and MSG-neonatally treated female mice, whereas the expression was increased only in MSG-neonatally treated male mice, but not in the intact males (Fig. 3, 4) . Though the high dose of Dex induced the expression of CYP2D9 mRNA in the females, but not in the males, the possibility that glucocorticoid at physiological concentration would not induce CYP2D9 mRNA expression cannot be excluded. Regarding the co-administration of Dex and GH to MSG-neonatally treated male mice, paradoxically, Dex antagonized the inductive eŠect of the pulsatile GH on CYP2D9 mRNA expression in the males. From our previous studies, expression of the sex-speciˆc P450s, such as CYP2B9, CYP3A41, and CYP3A44, is diŠerently regulated by collaboration of Dex and GH. A female-speciˆc CYP2B9 mRNA expression is markedly suppressed by Dex, 19) while it is signiˆcantly induced by the female type administered GH, 30) in which those of expression are oppositely conducted in male-speciˆc CYP2D9 mRNA expression (Fig. 3) . DiŠerently, either Dex or female type administered GH up-regulate female-speciˆc CYP3A41 and CYP3A44 mRNA expressions. 21, 23, 35) The increase of CYP2D9 mRNA expression by Dex, only in the females (Fig. 4) , might be because CYP2D9 is a male-speciˆc P450 species, and consequently the level of constitutive expression is already high in the males. In addition, the Dex-inducible CYP2D9 mRNA expression in adrenalectomized mice lately suggested that glucocorticoid or adrenal hormones partly participated in the regulation of CYP2D9 mRNA expression.
Understanding the way in which drug induce P450s is biologically relevant because it ultimately leads to better models for screening and predicting drug interactions that occur due to the induction of individual P450s. Since Dex is widely used as a clinical drug and extensively administered concurrently with medications, investigation of factor(s) associated with the sexually dimorphic expression of Cyp2d9 gene is a particular aspect to explain its diŠerent responses and to further understand the regulatory mechanism in human orthologous P450s. The liver-enriched nuclear receptors, GR and PXR, have been suggested to participate in the transcription of P450s, in which GR was activated under either physiological or pharmacological conditions, but PXR could exert a role under pharmacological condition. [37] [38] [39] It is arresting to identify responsible receptor(s). By injection, both pharmacological and physiological conditions are occurred, hence it is apparently unmanageable to maintain or simulate a real physiological condition of endocrines by exogenous administration.
We have reported that the modulation of femalespeciˆc CYP2B9 and CYP3A41 mRNAs expression certainly re‰ected their protein expression levels or enzyme activities of the relative P450s. 19, 20, 22) Considering herewith the CYP2D9 mRNA expression level in the present study, the evidences accomplished the association of GH and glucocorticoid hormone on the regulatory mechanism of its expression, consequently its protein expression level may be applicably considerable at best in part.
In conclusion, GH secretory proˆle is an essential regulatory factor for CYP2D9 mRNA expression in male mice, in which the expression is suppressible by exogenous GH-repetition. Besides GH, glucocorticoid or adrenal hormone partially plays a role in the regulatory mechanism of CYP2D9 mRNA expression.
